Skip to main content
SpringerLink
Log in

DAF as a Therapeutic Target for Steroid Hormones: Implications for Host–Pathogen Interactions

  • Chapter
  • First Online:
Complement Therapeutics

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 735))

Abstract

In this chapter, we present a concise historic prospective and a summary of accumulated knowledge on steroid hormones, DAF expression, and therapeutic implication of steroid hormone treatment on multiple pathologies, including infection and the host–pathogen interactions. DAF/CD55 plays multiple physiologic functions including tissue protection from the cytotoxic complement injury, an anti-inflammatory function due to its anti-adherence properties which enhance transmigration of monocytes and macrophages and reduce tissue injury. DAF physiologic functions are essential in many organ systems including pregnancy for protection of the semiallogeneic fetus or for preventing uncontrolled infiltration by white cells in their pro- and/or anti-inflammatory functions. DAF expression appears to have multiple regulatory tissue-specific and/or menstrual cycle-specific mechanisms, which involve complex signaling mechanisms. Regulation of DAF expression may involve a direct or an indirect effect of at least the estrogen, progesterone, and corticosteroid regulatory pathways. DAF is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. The binding of Escherichia coli bearing Dr adhesins to the DAF/CD55 receptor is DAF density dependent and triggers internalization of E. coli via an endocytic pathway involving CD55, lipid rafts, and microtubules. Dr+ E. coli or Dr antigen may persist in vivo in the interstitium for several months. Further understanding of such processes should be instrumental in designing therapeutic strategies for multiple conditions involving DAF’s protective or pathologic functions and tailoring host expression of DAF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akira S (2003) Toll-like receptor signaling. J Biol Chem 278:38105–38108

    Article  CAS  PubMed  Google Scholar 

  • Anderson GG, Palermo JJ, Schillin JD, Roth R, Heuser J, Hultgren SJ (2003) Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105–107

    Article  CAS  PubMed  Google Scholar 

  • Andoh A, Fujiyama Y, Sumiyoshi K, Sakumoto H, Okabe H, Bamba T (1997) Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells. Immunology 90:358–363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bergelson JM, Chan M, Solomon KR, St John NF, Lin H, Finberg RW (1994) Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 91:6245–6249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bergelson JM, Mohanty JG, Crowell RL, St John NF, Lublin DM, Finberg RW (1995) Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 69:1903–1906

    CAS  PubMed  PubMed Central  Google Scholar 

  • Curran E, Tassell AH, Judy BM, Nowicki B, Montgomery-Rice V, Estes DM, Nowicki S (2007) Estrogen increases menopausal host susceptibility to experimental ascending urinary tract infection. J Infect Dis 195:680–683

    Article  PubMed  Google Scholar 

  • Fang L, Nowicki B, Yallampalli C (2001) Differential expression of uterine nitric oxide system in pregnant and nonpregnant rats with intrauterine bacterial infection. Am J Physiol Regul Integr Comp Physiol 280:R1356–R1363

    Article  CAS  PubMed  Google Scholar 

  • Fang L, Nowicki BJ, Urvil P, Goluszko P, Nowicki S, Young SL, Yallampalli C (2004) Epithelial invasion by Escherichia coli bearing Dr fimbriae is controlled by nitric oxide-regulated expression of CD55. Infect Immun 72:2907–2914

    Article  PubMed  PubMed Central  Google Scholar 

  • Goluszko P, Moseley S, Truong LD, Kaul A, Nowicki S, Nowicki B (1997) Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H- bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis. J Clin Invest 99:1–11

    Article  Google Scholar 

  • Hart A, Nowicki BJ, Reisner B, Pawelczyk E, Goluszko P, Urvil P, Anderson G, Nowicki S (2001) Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin. J Infect Dis 183:1526–1529

    Article  CAS  PubMed  Google Scholar 

  • Hoffmann EM (1969) Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stroma. Immunochemistry 6:391–403

    Article  CAS  Google Scholar 

  • Holla VR, Wang D, Brown JR, Mann JR, Katkuri S, DuBois RN (2005) Prostaglandin E2 regulates the complement inhibitor CD55/decay accelerating factor in colorectal cancer. J Biol Chem 280:476–483

    Article  CAS  PubMed  Google Scholar 

  • Holmes CH, Simpson KL, Okada H, Okada N, Wainwright SD, Purcell DF, Houlihan JM (1992) Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 22: 1579–1585

    Article  CAS  PubMed  Google Scholar 

  • Kaul AK, Nowicki BJ, Martens MG, Goluszko P, Hart AR, Nagamani M, Kumar D, Pham T, Nowicki S (1994) Decay accelerating factor (DAF) is expressed in the human endometrium and may serve as the natural ligand for Dr pili of Escherichia coli. Am J Reprod Immunol 32:194–199

    Article  CAS  PubMed  Google Scholar 

  • Kaul A, Nagamani M, Nowicki B (1995) Decreased expression of endometrial decay accelerating factor (DAF), a complement regulatory protein, in patients with luteal phase defect. Am J Reprod Immunol 34:236–240

    Article  CAS  PubMed  Google Scholar 

  • Kaul A, Goluszko PG, Hart A, Martens M, Pham T, Nowicki S, Nowicki B (1996) Rapid cycle changes in density and accessibility of endometrial ligands for Escherichia coli Dr fimbriae. Infect Immun 64:611–615

    CAS  PubMed  PubMed Central  Google Scholar 

  • Louis NA, Kong T, Hamilton KE, Colgan SP (2005a) HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J 19:950–959

    Article  CAS  PubMed  Google Scholar 

  • Louis NA, Hamilton KE, Kong T, Colgan SP (2005b) HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J 19:950–959

    Article  CAS  PubMed  Google Scholar 

  • Mason JC, Steinberg R, Lidington EA, Kinderlerer AR, Ohba M, Haskard DO (2004) Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A. J Biol Chem 279:41611–41618

    Article  CAS  PubMed  Google Scholar 

  • Moulds JM, Nowicki S, Nowicki BJ, Moulds JJ (1996) Human blood groups: incidental receptors for viruses and bacteria. Transfusion 36:362–374

    Article  CAS  PubMed  Google Scholar 

  • Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF (1983) Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 80:5066–5070

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nowicki B (2002) Urinary tract infection in pregnant women: old dogmas and current concepts. Curr Infect Dis Rep 4:529–535

    Article  PubMed  Google Scholar 

  • Nowicki B, Hull R, Moulds J (1988a) Use of the Dr hemagglutinin of uropathogenic Escherichia coli to differentiate normal from abnormal red cells in paroxysmal nocturnal hemoglobinuria. N Eng J Med 319:1289–1290

    Article  CAS  Google Scholar 

  • Nowicki B, Moulds J, Hull R, Hull S (1988b) A hemagglutinin of uropathogenic E. coli recognized the Dr blood group antigen. Infect Immun 56:1057–1060

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nowicki B, Truong L, Moulds J, Hull R (1988c) Presence of the Dr receptor in normal human tissues and its possible role in pathogenesis of ascending urinary tract infection. Am J Pathol 133:1–4

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nowicki B, Fang L, Singhal S, Nowicki S, Yallampalli C (1997) Lethal outcome of uterine infection in pregnant but not in nonpregnant rats and increased death rate with inhibition of nitric oxide. Am J Reprod Immunol 38:309–312

    Article  CAS  PubMed  Google Scholar 

  • Nowicki S, Nowicki B, Pham T, Hasan R, Nagamani M (2001) Expression of decay accelerating factor (DAF) in endometrial adenocarcinoma is inversely related to the stage of tumor. Am J Reprod Immunol 46:144–148

    Article  CAS  PubMed  Google Scholar 

  • Nowicki S, Izban M, Pawelczyk E, Agboto V, Pratap S, Olson G, Nowicki B (2009) Preterm labor: CD55 in maternal blood leukocytes. Am J Rep Immunol 61:360–367

    Article  CAS  Google Scholar 

  • Nowicki B, Sledzinska A, Samet A, Nowicki S (2011a) Pathogenesis of gestational UTI: urinary obstruction vs. immune adaptation and microbial virulence. BJOG 218:109–112

    Article  Google Scholar 

  • Nowicki S, Rana T, Singh R, Nowicki B (2011) Dexamethasone treatment downregulates DAF and decrease intracellular survival of Dr  +  E. coli in HeLa cells. In: Proceedings of the 5th international conference on complement therapeutics, abstract 18, Rhodes, 22–27 June 2011

    Google Scholar 

  • O’Brien DP, Israel DA, Krishna U, Romero-Gallo J, Nedrud J, Medof ME, Lin F, Redline R, Lublin DM, Nowicki BJ, Franco AT, Ogden S, Williams AD, Polk DB, Peek RM Jr (2006) The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation. J Biol Chem 281:13317–13323

    Article  PubMed  Google Scholar 

  • Orlander JD, Jick SS, Dean AD, Jick H (1992) Urinary tract infections and estrogen use in older women. J Am Geriatr Soc 40:817–820

    Article  CAS  PubMed  Google Scholar 

  • Pacheco LD, Hankins GD, Costantine MM, Anderson GD, Pawelczyk E, Nowicki S, Nowicki BJ (2011) The role of human decay-accelerating factor in the pathogenesis of preterm labor. Am J Perinatol 28:565–570

    Article  PubMed  Google Scholar 

  • Pangburn MK, Schreiber RD, Muller-Eberhard HJ (1983) Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 80:5430–5434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sartini D, Moussawi M, Sallam R, Bernstein I, Huber S (2004) Correlation between serum estradiol in the follicular phase of the ovarian cycle and decay acceleration factor (DAF) expression on red blood cells and coxsackievirus B-3 induced hemagglutination in young cycling women. Am J Reprod Immunol 51:180–187

    Article  PubMed  Google Scholar 

  • Schreiber J, Jenner RG, Murray HL, Gerber GK, Gifford DK, Young RA (2006) Coordinated binding of NF-kB family members in the response of human cells to lipopolysaccharide. Proc Natl Acad Sci USA 103:5899–5904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Selvarangan R, Goluszko P, Popov V, Singhal J, Pham T, Lublin DM, Nowicki S, Nowicki B (2000) Role of decay-accelerating factor domains and anchorage in internalization of Dr. fimbriated Escherichia coli. Infect Immun 68:1391–1399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Śledzińska A, Mielech A, Krawczyk B, Samet A, Nowicki B, Nowicki S, Jankowski Z, Kur J (2011) Fatal sepsis in a pregnant woman with chronic pyelonephritis caused by Escherichia coli bearing Dr and P adhesins: diagnosis based on postmortem strain genotyping. BJOG 18:266–269

    Article  Google Scholar 

  • Song WC, Deng C, Raszmann K, Moore R, Newbold R, McLachlan JA, Negishi M (1996) Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol 157:4166–4172

    CAS  PubMed  Google Scholar 

  • Spiller OB, Criado-Garcia O, Rodriguez DC, Morgan BP (2000) Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 121:234–241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yallampalli C, Izumi H, Byam-Smith M, Garfield RE (1994) An l-arginine-nitric oxide-cyclic guanosine monophosphate system exists in the uterus and inhibits contractility during pregnancy. Am J Obstet Gynecol 170:175–185

    CAS  PubMed  Google Scholar 

  • Young SL, Lessey BA, Fritz MA, Meyer WR, Murray MJ, Speckman PL, Nowicki BJ (2002) In vivo and in vitro evidence suggests that HB-EGF regulates endometrial expression of human decay-accelerating factor. J Clin Endocrinol Metab 87:1368–1375

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Meharry Medical College, 1005 Dr DB Todd Jr. Bulvd, Nashville, TN, 37208, USA

    Bogdan Nowicki

  2. Department of Microbiology and Immunology, Meharry Medical College, 1005 Dr DB Todd Jr. Bulvd, Nashville, TN, 37208, USA

    Bogdan Nowicki & Stella Nowicki

Authors
  1. Bogdan Nowicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stella Nowicki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bogdan Nowicki .

Editor information

Editors and Affiliations

  1. Medicine, University Of Pennsylvania Department Of Pathology Laboratory Of, Philadelphia, Pennsylvania, USA

    John D. Lambris

  2. University of Colorado School of Medicin, Aurora, Colorado, USA

    V. Michael Holers

  3. Department of Pathology & Laboratory Med, University of Pennsylvania School of Med, Philadelphia, Pennsylvania, USA

    Daniel Ricklin

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Nowicki, B., Nowicki, S. (2013). DAF as a Therapeutic Target for Steroid Hormones: Implications for Host–Pathogen Interactions. In: Lambris, J., Holers, V., Ricklin, D. (eds) Complement Therapeutics. Advances in Experimental Medicine and Biology, vol 735. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4118-2_5

Download citation

Publish with us

Policies and ethics

Search

Navigation